nach oben

Erschienen in:

29.01.2018 | Original Paper

Serum levels of a cell death biomarker predict the development of cirrhosis-related conditions in primary biliary cholangitis

verfasst von: Manabu Hayashi, Kazumichi Abe, Masashi Fujita, Ken Okai, Atsushi Takahashi, Yoshihiro Nozawa, Hiromasa Ohira

Erschienen in: Medical Molecular Morphology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Non-invasive predictors for the development of cirrhosis-related conditions are needed for patients with primary biliary cholangitis (PBC). We investigated the association between cytokeratin-18 fragments (M30 and M65) and liver histology, treatment response and the development of cirrhosis-related conditions in patients with PBC. We retrospectively reviewed the clinical data of 111 individuals with biopsy-proven PBC. Serum M30 and M65 levels were measured using stored sera. M30 were significantly decreased after treatment, but there was no significant change in the M65 levels. M65 was significantly higher in non-responders according to the Paris-I and Paris-II definitions. In the multivariate analysis, high levels of M65 were significantly associated with advanced Scheuer stage (odds ratio 5.86; 95% confidence interval 0.55–22.2; P = 0.009) and with the development of cirrhosis-related conditions (hazard ratio 3.94; 95% confidence interval: 1.06–14.5, P = 0.039). Among PBC patients without cirrhosis, those with high serum M65 levels at baseline were at higher risk of developing cirrhosis-related conditions (log-rank test; P = 0.001). High levels of serum M65 may be a non-invasive and early predictor of the development of cirrhosis-related conditions in PBC patients. Our findings may help initiate therapies earlier for those at risk for cirrhosis.

Kaplan MM, Gershwin ME (2005) Primary biliary cirrhosis. N Engl J Med 353:1261–1273CrossRefPubMed

Selmi C, Bowlus CL, Gershwin ME, Coppel RL (2011) Primary biliary cirrhosis. Lancet 377:1600–1609CrossRefPubMed

Poupon R, Chretien Y, Chazouilleres O, Poupon RE (2005) Pregnancy in women with ursodeoxycholic acid-treated primary biliary cirrhosis. J Hepatol 42:418–419CrossRefPubMed

European Association for the Study of the Liver (2017) EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol 67:145–172CrossRef

Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ (1997) Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 113:884–890CrossRefPubMed

Corpechot C, Carrat F, Bonnand AM, Poupon RE, Poupon R (2000) The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 32:1196–1199CrossRefPubMed

Kuiper EM, Hansen BE, Metselaar HJ, de Man RA, Haagsma EB, van Hoek B, van Buuren HR (2010) Trends in liver transplantation for primary biliary cirrhosis in the Netherlands 1988–2008. BMC Gastroenterol 10:144CrossRefPubMedPubMedCentral

Silveira MG, Brunt EM, Heathcote J, Gores GJ, Lindor KD, Mayo MJ (2010) American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis. Hepatology 52:349–359CrossRefPubMed

Corpechot C, Chazouilleres O, Poupon R (2011) Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol 55:1361–1367CrossRefPubMed

10.

Kakuda Y, Harada K, Sawada-Kitamura S, Ikeda H, Sato Y, Sasaki M, Okafuji H, Mizukoshi E, Terasaki S, Ohta H, Kasashima S, Kawashima A, Kaizaki Y, Kaneko S, Nakanuma Y (2013) Evaluation of a new histologic staging and grading system for primary biliary cirrhosis in comparison with classical systems. Hum Pathol 44:1107–1117CrossRefPubMed

11.

Azemoto N, Abe M, Murata Y, Hiasa Y, Hamada M, Matsuura B, Onji M (2009) Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis. J Gastroenterol 44:630–634CrossRefPubMed

12.

Kumagi T, Guindi M, Fischer SE, Arenovich T, Abdalian R, Coltescu C, Heathcote EJ, Hirschfield GM (2010) Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol 105:2186–2194CrossRefPubMed

13.

Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD, American Association for the Study of Liver Diseases (2009) Liver biopsy. Hepatology 49:1017–1044CrossRefPubMed

14.

Van Eyken P, Desmet VJ (1993) Cytokeratins and the liver. Liver 13:113–122CrossRefPubMed

15.

Caulin C, Salvesen GS, Oshima RG (1997) Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J Cell Biol 138:1379–1394CrossRefPubMedPubMedCentral

16.

Ku NO, Liao J, Omary MB (1997) Apoptosis generates stable fragments of human type I keratins. J Biol Chem 272:33197–33203CrossRefPubMed

17.

Bantel H, Ruck P, Gregor M, Schulze-Osthoff K (2001) Detection of elevated caspase activation and early apoptosis in liver diseases. Eur J Cell Biol 80:230–239CrossRefPubMed

18.

Denk G, Omary AJ, Reiter FP, Hohenester S, Wimmer R, Holdenrieder S, Rust C (2014) Soluble intracellular adhesion molecule, M30 and M65 as serum markers of disease activity and prognosis in cholestatic liver diseases. Hepatol Res 44:1286–1298CrossRefPubMed

19.

Sekiguchi T, Umemura T, Fujimori N, Shibata S, Ichikawa Y, Kimura T, Joshita S, Komatsu M, Matsumoto A, Tanaka E, Ota M (2015) Serum cell death biomarkers for prediction of liver fibrosis and poor prognosis in primary biliary cirrhosis. PLoS One 10:e0131658CrossRefPubMedPubMedCentral

20.

Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ, American Association for Study of Liver Diseases (2009) Primary biliary cirrhosis. Hepatology 50:291–308CrossRefPubMed

21.

Scheuer P (1967) Primary biliary cirrhosis. Proc R Soc Med 60:1257–1260PubMedPubMedCentral

22.

Nakanuma Y, Zen Y, Harada K, Sasaki M, Nonomura A, Uehara T, Sano K, Kondo F, Fukusato T, Tsuneyama K, Ito M, Wakasa K, Nomoto M, Minato H, Haga H, Kage M, Yano H, Haratake J, Aishima S, Masuda T, Aoyama H, Miyakawa-Hayashino A, Matsumoto T, Sanefuji H, Ojima H, Chen TC, Yu E, Kim JH, Park YN, Tsui W (2010) Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: Interobserver agreement. Pathol Int 60:167–174CrossRefPubMed

23.

Bantel H, Lugering A, Heidemann J, Volkmann X, Poremba C, Strassburg CP, Manns MP, Schulze-Osthoff K (2004) Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 40:1078–1087CrossRefPubMed

24.

Corpechot C, Abenavoli L, Rabahi N, Chretien Y, Andreani T, Johanet C, Chazouilleres O, Poupon R (2008) Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 48:871–877CrossRefPubMed

25.

Pares A, Caballeria L, Rodes J (2006) Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology 130:715–720CrossRefPubMed

26.

Kuiper EM, Hansen BE, de Vries RA, den Ouden-Muller JW, van Ditzhuijsen TJ, Haagsma EB, Houben MH, Witteman BJ, van Erpecum KJ, van Buuren HR, Dutch P. B. C. Study Group (2009) Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 136:1281–1287CrossRefPubMed

27.

Lammers WJ, Hirschfield GM, Corpechot C, Nevens F, Lindor KD, Janssen HL, Floreani A, Ponsioen CY, Mayo MJ, Invernizzi P, Battezzati PM, Pares A, Burroughs AK, Mason AL, Kowdley KV, Kumagi T, Harms MH, Trivedi PJ, Poupon R, Cheung A, Lleo A, Caballeria L, Hansen BE, van Buuren HR, Global PBC Study Group (2015) Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology 149:1804–1812 (e1804)CrossRefPubMed

28.

Carbone M, Sharp SJ, Flack S, Paximadas D, Spiess K, Adgey C, Griffiths L, Lim R, Trembling P, Williamson K, Wareham NJ, Aldersley M, Bathgate A, Burroughs AK, Heneghan MA, Neuberger JM, Thorburn D, Hirschfield GM, Cordell HJ, Alexander GJ, Jones DE, Sandford RN, Mells GF, UK-PBC Consortium (2016) The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology 63:930–950CrossRefPubMed

29.

Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458CrossRefPubMed

30.

Namisaki T, Moriya K, Kitade M, Kawaratani H, Takeda K, Okura Y, Takaya H, Nishimura N, Seki K, Kaji K, Sato S, Sawada Y, Yamao J, Mitoro A, Uejima M, Mashitani T, Shimozato N, Nakanishi K, Furukawa M, Saikawa S, Kubo T, Yoshiji H (2017) Clinical significance of the Scheuer histological staging system for primary biliary cholangitis in Japanese patients. Eur J Gastroenterol Hepatol 29:23–30CrossRefPubMed

31.

Koga H, Sakisaka S, Ohishi M, Sata M, Tanikawa K (1997) Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis. Hepatology 25:1077–1084CrossRefPubMed

32.

Fox CK, Furtwaengler A, Nepomuceno RR, Martinez OM, Krams SM (2001) Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis. Liver 21:272–279CrossRefPubMed

33.

Fickert P, Wagner M (2017) Biliary bile acids in hepatobiliary injury—what is the link? J Hepatol 67:619–631CrossRefPubMed

34.

Medina JF, Martinez A, Vazquez JJ, Prieto J (1997) Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. Hepatology 25:12–17CrossRefPubMed

35.

Prieto J, Garcia N, Marti-Climent JM, Penuelas I, Richter JA, Medina JF (1999) Assessment of biliary bicarbonate secretion in humans by positron emission tomography. Gastroenterology 117:167–172CrossRefPubMed

36.

Beuers U (2006) Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 3:318–328CrossRefPubMed

37.

Sola S, Amaral JD, Castro RE, Ramalho RM, Borralho PM, Kren BT, Tanaka H, Steer CJ, Rodrigues CM (2005) Nuclear translocation of UDCA by the glucocorticoid receptor is required to reduce TGF-beta1-induced apoptosis in rat hepatocytes. Hepatology 42:925–934CrossRefPubMed

Titel: Serum levels of a cell death biomarker predict the development of cirrhosis-related conditions in primary biliary cholangitis
verfasst von: Manabu Hayashi
Kazumichi Abe
Masashi Fujita
Ken Okai
Atsushi Takahashi
Yoshihiro Nozawa
Hiromasa Ohira
Publikationsdatum: 29.01.2018
Verlag: Springer Japan
Erschienen in: Medical Molecular Morphology / Ausgabe 3/2018
Print ISSN: 1860-1480
Elektronische ISSN: 1860-1499
DOI: https://doi.org/10.1007/s00795-018-0184-0

Neu im Fachgebiet Pathologie

01.04.2024 | Forensische Traumatologie | CME

Springer Medizin

Serum levels of a cell death biomarker predict the development of cirrhosis-related conditions in primary biliary cholangitis

Abstract

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Morphological and molecular characterization of the senile osteoporosis in senescence-accelerated mouse prone 6 (SAMP6)

Novel Rest functions revealed by conditional gene ablation

Effect of systemic administration of lipopolysaccharides derived from Porphyromonas gingivalis on gene expression in mice kidney

Characteristics of pericytes in diethylstilbestrol (DES)-induced pituitary prolactinoma in rats

Morphological characterization of pulmonary microvascular disease in bronchopulmonary dysplasia caused by hyperoxia in newborn mice

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien